Compare PVL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PVL | CALC |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 63.0M |
| IPO Year | N/A | N/A |
| Metric | PVL | CALC |
|---|---|---|
| Price | $1.79 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 74.4K | ★ 132.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 19.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $3,511,891.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.44 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $1.42 |
| 52 Week High | $2.04 | $5.34 |
| Indicator | PVL | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 65.93 |
| Support Level | $1.78 | $4.24 |
| Resistance Level | $1.90 | $5.34 |
| Average True Range (ATR) | 0.05 | 0.41 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 17.26 | 73.24 |
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.